(EMAILWIRE.COM, May 23, 2025 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Microbiome Diagnostics Market (By Product (Reagents & Kits, Instruments), By Technology (16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics, Other Technology), By Sample (Feces, Saliva, Skin, Other Sample), By Application (Disease Diagnostics Application (Gastrointestinal Disorders, Metabolic Diseases, Other Application), Research Application), By End-User (Hospitals, Academic and Research Institutes, Biotechnology and Pharmaceutical Companies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Microbiome Diagnostics Market is valued at US$ 154.9 Mn in 2023, and it is expected to reach US$ 488.2 Mn by 2031, with a CAGR of 15.6% during the forecast period of 2024-2031.
Global Microbiome Diagnostics Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2398
Microbiome diagnostics involves the analysis of microbial communities present within and on the human body to identify changes associated with various diseases, disorders, or overall health conditions. The human microbiomewhich includes bacteria, viruses, fungi, and other microorganismsplays a critical role in numerous physiological functions, including digestion, immune response, and even neurological behavior. Advances in technology and bioinformatics have significantly enhanced the accuracy and comprehensiveness of microbiome profiling.
These developments have led to the emergence of innovative diagnostic solutions applicable to areas such as infectious disease detection, personalized medicine, and gastrointestinal health. The market is further propelled by increased investments in microbiome research and growing collaboration between academic institutions and biotechnology companies.
Nevertheless, challenges remain, particularly concerning regulatory frameworks and the need for standardized testing methodologies, which continue to influence the evolution of this dynamic and rapidly developing sector.
List of Prominent Players in the Microbiome Diagnostics Market:
Yakult Honsha Co.
AOBiome
Enterome Biosciences SA
Metabiomics Corp. (BioSpherex LLC)
Microbiome Therapeutics LLC
Osel, Inc.
Rebiotix, Inc.
Second Genome
Seres Therapeutics
Synthetic Biologics, Inc.
Vedanta Biosciences
4D Pharma
Du Pont De Nemours and Co.
Ferring Pharmaceuticals
Genetic Analysis AS
Atlas Biomed
Biome Oxford Ltd.
Illumina Inc.
Microba Life Sciences
Dna Genotek (Orasure Technologies, Inc.)
Viome Life Sciences
Sun Genomics
Becton, Dickinson And Company
Daytwo
OraSure Technologies, Inc.
Other Market Players
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
Ongoing research and educational initiatives centered on the human microbiome are primary drivers of growth in the microbiome diagnostics market. Collaborations between academic institutions and industry stakeholders are fostering the development of advanced microbiome-based diagnostic tools and expanding understanding of the microbiome’s influence on health and disease.
These strategic partnerships are facilitating the translation of foundational scientific discoveries into practical clinical applications, thereby generating new opportunities for microbiome-driven diagnostics. Continued scientific exploration is deepening insights into the microbiomes role in human health, increasing demand for diagnostic solutions.
Additionally, educational programs aimed at healthcare professionals and the general public are promoting awareness and encouraging the adoption of personalized, microbiome-based diagnostic approaches, ultimately supporting improved patient outcomes. Rising interest in healthy lifestyles is also contributing to market expansion.
Challenges:
High production and processing costs pose a significant barrier to market growth. The complexity of manufacturing methodssuch as compression molding and continuous laminationcontributes to elevated expenses. Furthermore, the limited availability of critical raw materials exacerbates these costs.
The high financial burden associated with research and development activities, coupled with insufficient infrastructure and gaps in comprehensive microbiome studies, further restricts market progression. Despite global efforts by governmental and private entities to fund microbiome research, many academic and research institutions continue to face financial constraints, limiting access to advanced and costly diagnostic technologies.
Regional Trends:
North America is projected to command a substantial share of the microbiome diagnostics market, supported by a robust healthcare infrastructure and the presence of key industry players. Regional growth is influenced by strong demand, technological advancements, and favorable economic conditions.
While developed regions are benefiting from established research ecosystems and export-oriented frameworks, emerging markets are witnessing increased demand driven by the need for innovative diagnostic solutions and expanding access to personalized healthcare.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2398
Recent Developments
In July 2022, OraSure Technologies, Inc. has made its OMNIgene®GUT DNA and RNA product (OMR-205) available to researchers studying the gut microbiota. OraSure technology is a prominent worldwide frontrunner in the field of point-of-care and home diagnostic testing, as well as sample collecting technology. The product facilitated the collection, preservation, storage, and transfer of microbial DNA and RNA at room temperature for the purpose of analyzing the gut microbiome. The product was manufactured by DNA Genotek, a subsidiary of OraSure.
In Aug 2021, A partnership between Second Genome and Arena Pharmaceuticals to identify gastrointestinal biomarkers was recently disclosed. A proof-of-concept study utilizing microbiome signals was conducted by Second Genome as part of Arena’s CULTIVATE Phase 2/3 clinical trial for Crohn’s disease.
Market Segmentation-
By Product-
Reagents & Kits
Instruments
By Technology-
16S rRNA Sequencing
Shot Gun Metagenomics
Metatranscriptomics
Other Technology
By Sample-
Feces
Saliva
Skin
Other Sample
By Application-
Disease Diagnostics Application
o Gastrointestinal Disorders
o Metabolic Diseases
o Other Application
Research Application
By End-User-
Hospitals
Academic and Research Institutes
Biotechnology and Pharmaceutical Companies
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/microbiome-diagnostics-market/2398
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
Insight Ace Analytics
Diana Dsouza
+1 551 226 6109
diana.dsouza@insightaceanalytics.com
Source link
